Tradestie Institutional Equity Comparison Engine
CRCA vs HOOZ โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
CRCA Overall Edge
CRCA Captures Institutional Edge (2โ0 Pillars ยท 3โ0 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to ProShares Ultra CRCL (CRCA) driven by superior Momentum & Technical, Options & Structure. Fundamentally, CRCA trades at N/M Forward P/E with N/A operating margin (N/A YoY revenue) versus HOOZ at N/M Forward P/E and N/A operating margin (N/A YoY). In options structure, CRCA sits in UNCLASSIFIED (<1st %ile IV; Dealer Gamma Walls on Pro) against HOOZ sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
CRCA N/M vs HOOZ N/M Fwd P/E
Growth & Margin Winner
Tie
Op Margin N/A vs N/A ยท YoY N/A vs N/A
Momentum & Technical Winner
CRCA
1Y +60.9% vs -64.9% ยท 52W Pos 7% vs 1%
Options & Structure Winner
CRCA
UNCLASSIFIED (<1st %ile IV) vs UNCLASSIFIED (N/A IV)
CRCA
NYSE Arca
ProShares Ultra CRCL
Institutional Equity
$7.83
-14.56% 1D
Market Cap
N/A
1M Return
-53.64%
1Y Return
+60.88%
Forward P/E
N/M
Unified AI Score
51.0 / 100
HOLD
Tech 53.0
Fund 54.0
Flow 50.0
Mom 60.0
HOOZ
US Equity
HOOZ
Institutional Equity
$8.22
-2.03% 1D
Market Cap
N/A
1M Return
-41.12%
1Y Return
-64.94%
Forward P/E
N/M
Unified AI Score
48.6 / 100
HOLD
Tech 50.0
Fund 49.0
Flow 50.0
Mom 45.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
CRCA +60.88%
HOOZ -64.94%
Spread: +490.81 pp (CRCA Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
CRCA TTM Op. Margin: N/A
HOOZ TTM Op. Margin: N/A
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CRCA vs HOOZ. Trailing 12-month operating profitability (CRCA N/A vs HOOZ N/A) and valuation multiples (CRCA N/M vs HOOZ N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | CRCA | HOOZ | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | N/A | N/A | Larger Scale | Tie |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | N/A | N/A | Higher Growth | Tie |
| Operating Margin (TTM) Profitability | N/A | N/A | Higher Margin | Tie |
| Net Profit Margin Profitability | N/A | N/A | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | N/A | N/A | Higher ROE | Tie |
| 52-Week Range Position Momentum | 7% ($1โ$93) | 1% ($8โ$49) | Stronger Trend | CRCA |
| Beta / 30D Volatility Risk Regime | 4.88ฮฒ ยท 137% Vol | -5.67ฮฒ ยท 139% Vol | Lower Realized Risk | CRCA |
| Unified Institutional Score Composite Signal | 51.0 / 100 (HOLD) | 48.6 / 100 (HOLD) | Higher Composite | CRCA |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full CRCA vs HOOZ Buy Guide
CRCA
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
<1st %ile
IV Regime
Compressed (<25th %ile)
HOOZ
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither CRCA nor HOOZ registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.